[go: up one dir, main page]

WO2014140989A3 - Combinaison d'un inhibiteur de l'egfr t790m et d'un inhibiteur de l'egfr dans le traitement d'un cancer du poumon non à petites cellules - Google Patents

Combinaison d'un inhibiteur de l'egfr t790m et d'un inhibiteur de l'egfr dans le traitement d'un cancer du poumon non à petites cellules Download PDF

Info

Publication number
WO2014140989A3
WO2014140989A3 PCT/IB2014/059401 IB2014059401W WO2014140989A3 WO 2014140989 A3 WO2014140989 A3 WO 2014140989A3 IB 2014059401 W IB2014059401 W IB 2014059401W WO 2014140989 A3 WO2014140989 A3 WO 2014140989A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
egfr
combination
lung cancer
small cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/059401
Other languages
English (en)
Other versions
WO2014140989A2 (fr
Inventor
Zelanna Iris GOLDBERG
John Charles Kath
Stephen Paul Letrent
Scott Lawrence Weinrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2015137596A priority Critical patent/RU2015137596A/ru
Priority to KR1020157024916A priority patent/KR20150119210A/ko
Priority to CN201480014630.2A priority patent/CN105073116A/zh
Priority to EP14710651.2A priority patent/EP2968336A2/fr
Priority to MX2015012106A priority patent/MX2015012106A/es
Priority to SG11201506531WA priority patent/SG11201506531WA/en
Priority to BR112015023020A priority patent/BR112015023020A2/pt
Priority to CA2904797A priority patent/CA2904797A1/fr
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Priority to AU2014229468A priority patent/AU2014229468A1/en
Publication of WO2014140989A2 publication Critical patent/WO2014140989A2/fr
Publication of WO2014140989A3 publication Critical patent/WO2014140989A3/fr
Priority to IL240730A priority patent/IL240730A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une méthode de traitement d'un cancer du poumon non à petites cellules par l'administration d'une combinaison d'un inhibiteur de l'EGFR T790M en association avec une faible dose d'un inhibiteur du panHER. L'invention a également trait à une méthode de traitement d'un cancer des poumons non à petites cellules par l'administration d'une combinaison d'un inhibiteur irréversible de l'EGFR T790M en association avec un inhibiteur de l'EGFR.
PCT/IB2014/059401 2013-03-14 2014-03-03 Combinaison d'un inhibiteur de l'egfr t790m et d'un inhibiteur de l'egfr dans le traitement d'un cancer du poumon non à petites cellules Ceased WO2014140989A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR112015023020A BR112015023020A2 (pt) 2013-03-14 2014-03-03 combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
CN201480014630.2A CN105073116A (zh) 2013-03-14 2014-03-03 治疗非小细胞肺癌的egfr t790m 抑制剂与egfr 抑制剂的组合
EP14710651.2A EP2968336A2 (fr) 2013-03-14 2014-03-03 Combinaison d'un inhibiteur de l'egfr t790m et d'un inhibiteur de l'egfr dans le traitement d'un cancer du poumon non à petites cellules
MX2015012106A MX2015012106A (es) 2013-03-14 2014-03-03 Combinacion de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cancer pulmonar de celulas no pequeñas.
SG11201506531WA SG11201506531WA (en) 2013-03-14 2014-03-03 Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer
RU2015137596A RU2015137596A (ru) 2013-03-14 2014-03-03 Комбинация ингибитора EGFR T790М и ингибитора EGFR для лечения немелкоклеточного рака легкого
KR1020157024916A KR20150119210A (ko) 2013-03-14 2014-03-03 비소세포 폐암의 치료를 위한 egfr t790m 억제제와 egfr 억제제의 조합
CA2904797A CA2904797A1 (fr) 2013-03-14 2014-03-03 Combinaison d'un inhibiteur de l'egfr t790m et d'un inhibiteur de l'egfr dans le traitement d'un cancer du poumon non a petites cellules
AU2014229468A AU2014229468A1 (en) 2013-03-14 2014-03-03 Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer
IL240730A IL240730A0 (en) 2013-03-14 2015-08-20 A combination of t790m egfr inhibitor and egfr inhibitor, for the treatment of non-small cell lung cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786130P 2013-03-14 2013-03-14
US61/786,130 2013-03-14

Publications (2)

Publication Number Publication Date
WO2014140989A2 WO2014140989A2 (fr) 2014-09-18
WO2014140989A3 true WO2014140989A3 (fr) 2014-12-04

Family

ID=50288209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/059401 Ceased WO2014140989A2 (fr) 2013-03-14 2014-03-03 Combinaison d'un inhibiteur de l'egfr t790m et d'un inhibiteur de l'egfr dans le traitement d'un cancer du poumon non à petites cellules

Country Status (14)

Country Link
EP (1) EP2968336A2 (fr)
JP (1) JP2014177456A (fr)
KR (1) KR20150119210A (fr)
CN (1) CN105073116A (fr)
AR (1) AR095197A1 (fr)
AU (1) AU2014229468A1 (fr)
BR (1) BR112015023020A2 (fr)
CA (1) CA2904797A1 (fr)
IL (1) IL240730A0 (fr)
MX (1) MX2015012106A (fr)
RU (1) RU2015137596A (fr)
SG (1) SG11201506531WA (fr)
TW (1) TW201446248A (fr)
WO (1) WO2014140989A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103814030A (zh) 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
CN104311573B (zh) 2013-09-18 2017-12-15 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
WO2016051380A1 (fr) * 2014-10-01 2016-04-07 Sun Pharmaceutical Industries Limited Forme cristalline de dimaléate d'afatinib
CN114224894B (zh) * 2014-12-03 2025-01-07 奥克兰联合服务有限公司 用于治疗癌症的激酶抑制剂前药
US10538518B2 (en) * 2015-08-11 2020-01-21 Principia Biopharma, Inc. Processes for preparing an FGFR inhibitor
US10583142B2 (en) 2016-03-25 2020-03-10 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods of treatment
WO2017164887A1 (fr) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Régime de dosage pulsé et procédés de traitement
WO2017176565A1 (fr) 2016-04-07 2017-10-12 Eli Lilly And Company Combinaisons d'un anticorps anti-b7-h1 et d'un agoniste du peptide cxcr4 pour le traitement d'une tumeur solide
WO2017200016A1 (fr) * 2016-05-17 2017-11-23 公益財団法人がん研究会 Agent thérapeutique pour le cancer bronchique ayant acquis une résistance à egfr-tki
US20190125751A1 (en) * 2016-05-18 2019-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
CA3055109A1 (fr) * 2017-03-08 2018-09-13 Ariad Pharmaceuticals, Inc. Formulations pharmaceutiques comprenant une 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine
CN111433208B (zh) * 2017-12-05 2023-06-30 奥斯考泰克公司 作为lrrk2抑制剂的吡咯并(吡唑并)嘧啶衍生物
US20240059698A1 (en) * 2022-07-29 2024-02-22 Accutar Biotechnology Inc. Heteroaryl compounds as egfr inhibitors and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013042006A1 (fr) * 2011-09-22 2013-03-28 Pfizer Inc. Dérivés de pyrrolopyrimidine et de purine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013042006A1 (fr) * 2011-09-22 2013-03-28 Pfizer Inc. Dérivés de pyrrolopyrimidine et de purine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE HO-JUNE ET AL: "Noncovalent wild-type-sparing inhibitors of EGFR T790M.", CANCER DISCOVERY, vol. 3, no. 2, February 2013 (2013-02-01), pages 168 - 181, XP002725587, ISSN: 2159-8290 *

Also Published As

Publication number Publication date
CN105073116A (zh) 2015-11-18
AR095197A1 (es) 2015-09-30
IL240730A0 (en) 2015-10-29
RU2015137596A (ru) 2017-04-17
BR112015023020A2 (pt) 2017-07-18
SG11201506531WA (en) 2015-09-29
EP2968336A2 (fr) 2016-01-20
TW201446248A (zh) 2014-12-16
MX2015012106A (es) 2016-01-12
WO2014140989A2 (fr) 2014-09-18
JP2014177456A (ja) 2014-09-25
AU2014229468A1 (en) 2015-09-03
KR20150119210A (ko) 2015-10-23
CA2904797A1 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
WO2014140989A3 (fr) Combinaison d'un inhibiteur de l'egfr t790m et d'un inhibiteur de l'egfr dans le traitement d'un cancer du poumon non à petites cellules
HK1245134A1 (zh) 用抗lap单克隆抗体治疗癌症
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
IL240060A0 (en) Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
IL243645A0 (en) Preparations, methods and kits for the diagnosis and treatment of diseases associated with cells expressing cd206
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
WO2013177187A3 (fr) Traitement de tumeur synergique avec du pk il-2 étendu et des agents thérapeutiques
HK1245246A1 (zh) 作为溴域抑制剂的取代吡啶酮
EP3038647A4 (fr) Polythérapie pour le traitement du glioblastome
WO2014165090A8 (fr) Composés pour le traitement de la tuberculose
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
WO2014151606A3 (fr) Procédés de traitement du cancer du pancréas
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
TN2014000443A1 (en) Biomarkers for iap inhibitor therapy
WO2015027121A3 (fr) Traitement contre le cancer
EP3302487A4 (fr) Compositions thérapeutiques contenant du dipyridamole, modules et trousses de traitement comprenant de telles compositions, et procédés de production de celles-ci
UA76756U (ru) Способ лечения псориаза
UA78646U (ru) Способ радиохимиотерапии немелкоклеточного рака легкого

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480014630.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14710651

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 240730

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2014229468

Country of ref document: AU

Date of ref document: 20140303

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2904797

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/012106

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20157024916

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014710651

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014710651

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015137596

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015023020

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015023020

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150914